Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis.
Vandevyvere
K
K
Division of Rheumatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Luyten
F P
FP
Division of Rheumatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Verschueren
P
P
Division of Rheumatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Lories
R
R
Division of Rheumatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Segaert
S
S
Division of Dermatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Westhovens
R
R
Division of Rheumatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. Rene.Westhovens@uz.kuleuven.be.
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D017511:Pyoderma Gangrenosum / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab